Key US Advisory Committee to Vote on Changing Baby Hepatitis B Vaccine Recommendation
Following a hold-up and an unusually contentious gathering, a national immunization advisory committee was scheduled to decide on Friday concerning altering the longstanding recommendation that each baby be inoculated against hepatitis B.
Heated Debate and a Postponed Decision
The opening session of the assembly on Thursday was marked by heated debate over curbing eligibility to the hepatitis B vaccine for newborns and a resolution to defer the vote by a day to provide committee members extra time to scrutinize the phrasing. The group, which advises the CDC on vaccine use, had previously delayed on two occasions.
“Is there any concrete proof of harm of giving this immunization before 30 days? Or is this speculation?” inquired one committee member.
In response, another attendee stated, “There is limited evidence about the enduring danger.”
Current Guidelines and Likely Ramifications
The injection is currently suggested for each baby within 24 hours of delivery to halt contraction of hepatitis B, which can result in significant hepatic injury. It has been given to 1.4 billion people for in excess of thirty years.
The Atlanta conference offered no new evidence of harms caused by the vaccine. Authorities state any modification to the present hepatitis B immunization timeline could have major and extensive consequences for infant and child health in the United States.
Panel Composition and Latest Shifts
The consultative group can only provide advice to the leader of the CDC. The panel's membership has seen shifts recently, with the declaration that the committee’s most recent chair would depart for an agency job and be replaced by a heart specialist who has been critical of other inoculations.
The committee includes a number of immunization doubters who support a desire to overhaul – and potentially, in some cases, abolish – long-established vaccination recommendations.
